MWS
ARQT icon

MFA Wealth Services’s Arcutis Biotherapeutics ARQT Stock Holding History

MFA Wealth Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$425K Hold
16,196
– – 0.25% 92
2026
Q1 		$382K Buy
+16,196
New +$413K 0.25% 92

Other funds holding ARQT

PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

MFA Wealth Services's ARQT Position: Q2 2026 in Review

MFA Wealth Services held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 16,196 shares worth $425K. The position accounts for 0.25% of the portfolio, ranked #92.

MFA Wealth Services first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • MFA Wealth Services held 16,196 shares of Arcutis Biotherapeutics worth $425K as of Q2 2026.
  • MFA Wealth Services left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 0.25% of MFA Wealth Services's portfolio in Q2 2026, its #92 holding.
  • MFA Wealth Services first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on MFA Wealth Services's 13F filing for Q2 2026, filed 22 Jul 2026.